Dongkook Pharmaceutical Co Stock Current Valuation
Valuation analysis of DongKook Pharmaceutical helps investors to measure DongKook Pharmaceutical's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
DongKook Pharmaceutical Co Company Current Valuation Analysis
DongKook Pharmaceutical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current DongKook Pharmaceutical Current Valuation | 1.08 T |
Most of DongKook Pharmaceutical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DongKook Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, DongKook Pharmaceutical Co has a Current Valuation of 1.08 T. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all Republic of Korea stocks is notably lower than that of the firm.
DongKook Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DongKook Pharmaceutical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DongKook Pharmaceutical could also be used in its relative valuation, which is a method of valuing DongKook Pharmaceutical by comparing valuation metrics of similar companies.DongKook Pharmaceutical is currently under evaluation in current valuation category among its peers.
DongKook Fundamentals
| Return On Equity | 12.72 | |||
| Return On Asset | 0.0608 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 1.08 T | |||
| Shares Outstanding | 8.79 M | |||
| Shares Owned By Insiders | 46.60 % | |||
| Shares Owned By Institutions | 17.00 % | |||
| Price To Earning | 19.52 X | |||
| Price To Sales | 0.24 X | |||
| Revenue | 594.19 B | |||
| Gross Profit | 337.12 B | |||
| EBITDA | 83.48 B | |||
| Net Income | 52.92 B | |||
| Cash And Equivalents | 85.44 B | |||
| Total Debt | 13.69 B | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 2.61 X | |||
| Book Value Per Share | 23,358 X | |||
| Cash Flow From Operations | 44.65 B | |||
| Target Price | 22667.0 | |||
| Number Of Employees | 1.06 K | |||
| Beta | 1.09 | |||
| Market Capitalization | 145.91 B | |||
| Total Asset | 750.08 B | |||
| Retained Earnings | 172.22 B | |||
| Working Capital | 139.53 B | |||
| Current Asset | 203.59 B | |||
| Current Liabilities | 64.06 B | |||
| Z Score | 6.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 750.08 B |
About DongKook Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DongKook Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DongKook Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DongKook Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in DongKook Stock
DongKook Pharmaceutical financial ratios help investors to determine whether DongKook Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DongKook with respect to the benefits of owning DongKook Pharmaceutical security.